# US 2026/0085318 A1 · Methods for Treating Cancer Using a Stat3 Double-Stranded, Cyclic Oligonucleotide Decoy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085318 A1
- Document ID: US20260085318A1
- Status: Published application
- Kind: A1
- Application number: 19/112,832
- Filed: 2023-09-20
- Published: 2026-03-26
- Earliest claimed: 2022-09-23
- Applicants: The Regents of the University of California
- Inventors: Daniel E. Johnson; Jennifer R. Grandis
- Web page: https://patentgrep.com/patent/US20260085318A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/39541: {against normal tissues, cells}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/11: Antisense
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides methods of treating cancer using a STAT3 double-stranded, cyclic oligonucleotide decoy in combination with an immune checkpoint inhibitor.

## Claims

### Claim 1

A method of treating cancer in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a STAT3 double-stranded, cyclic oligonucleotide decoy and an immune checkpoint inhibitor, to treat the cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the immune checkpoint inhibitor is an inhibitor of PD-1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

### Claim 4 (depends on 1)

The method of claim 1, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, dostarlimab, durvalumab, or avelumab.

### Claim 5 (depends on 1)

The method of claim 1, wherein the immune checkpoint inhibitor is an inhibitor of PD-L1.

### Claim 6 (depends on 1)

The method of claim 1, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.

### Claim 7 (depends on 1)

The method of claim 1, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody selected from atezolizumab, avelumab, or durvalumab.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the STAT3 double-stranded, cyclic oligonucleotide decoy comprises a sense strand, an antisense strand, a first carbon-containing linker that binds the 3′ end of the sense strand to the 5′ end of the antisense strand, and a second carbon-containing linker that binds the 5′ end of the sense strand to the 3′ end of the antisense strand, wherein the sense strand comprises the sequence 5′-CATTTCCCGTAAATC-3′ (SEQ ID NO: 1).

### Claim 9 (depends on 8)

The method of claim 8, wherein the sense strand is up to 18 nucleotides long.

### Claim 10 (depends on 8)

The method of claim 8, wherein the sense strand consists of the sequence 5′-CATTTCCCGTAAATC-3′ (SEQ ID NO: 1).

### Claim 11 (depends on 8, 9, 10)

The method of any one of claims 8-10, wherein the antisense strand is at least partially complementary to the sense strand.

### Claim 12 (depends on 8, 9, 10)

The method of any one of claims 8-10, wherein the antisense strand is fully complementary to the sense strand.

### Claim 13 (depends on 8, 9, 10, 11, 12)

The method of any one of claims 8-12, wherein the sense strand has a phosphodiester backbone.

### Claim 14 (depends on 8, 9, 10, 11, 12, 13)

The method of any one of claims 8-13, wherein the antisense strand has a phosphodiester backbone.

### Claim 15 (depends on 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 8-14, wherein the first carbon-containing linker comprises one or more ethylene glycolyl.

### Claim 16 (depends on 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 8-14, wherein the first carbon-containing linker comprises hexaethylene glycolyl.

### Claim 17 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 8-16, wherein the second carbon-containing linker comprises one or more ethylene glycolyl.

### Claim 18 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 8-16, wherein the second carbon-containing linker comprises hexaethylene glycolyl.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the cancer is a head and neck cancer, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, prostate cancer, skin cancer, cervical cancer, oral cancer, esophageal cancer, bladder cancer, leukemia, lymphoma, or a glioma.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the cancer is a head and neck cancer.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the cancer is lung cancer.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the cancer is colorectal cancer, pancreatic cancer, ovarian cancer, or melanoma.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22. wherein the cancer is a squamous cell carcinoma.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the cancer is recurrent.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1-24, wherein the cancer is metastatic.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the patient is a human.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the STAT3 double-stranded, cyclic oligonucleotide decoy is administered simultaneously with the immune checkpoint inhibitor.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the STAT3 double-stranded, cyclic oligonucleotide decoy and immune checkpoint inhibitor are administered sequentially.
